세계의 생균치료제 및 미생물 CDMO 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 지역별, 부문 예측(2025-2030년)

Live Biotherapeutic Products And Microbiome CDMO Market Growth & Trends:

The global live biotherapeutic products and microbiome CDMO market size is expected to reach USD 397.49 million by 2030, expanding at a CAGR of 38.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market has been growing quickly in recent years, and this trend is anticipated to continue. The rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating various diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.

The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows. This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years.

Due to the increasing complexity of developing these therapies, outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies. For instance, in July 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company, announced a USD 26.30 million Series A funding to advance the clinical development of its therapeutic pipeline, which includes several clinical trials of EXL01. EXL01 is a novel immunotherapy with applications in infectious diseases and cancer.

Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, in October 2023, Ferring Pharmaceuticals announced two presentations at the American College of Gastroenterology's 2023 Annual Scientific Meeting for REBYOTA. It is the first single-dose microbiome-based treatment approved by the U.S. FDA to prevent recurrent C. difficile Infection (CDI) in adults aged 18 & above following antibiotic treatment for recurrent CDI. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.

The COVID-19 pandemic has significantly impacted the market for live biotherapeutic products and microbiome contract development and manufacturing organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.

Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights:

• C.difficle held the largest revenue share in 2024 owing to the increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the live biotherapeutic products and microbiome contract development and manufacturing market.
• Many companies focus on developing and manufacturing products for treating C.difficle infections, driving the market's expansion.
• North America live biotherapeutic products and microbiome CDMO market accounted for the largest share of 76.84% in 2024 of the global live biotherapeutic products and microbiome market.
• Asia Pacific is expected to grow at a CAGR of 44.82% during the forecast period. The market in Asia Pacific has witnessed significant growth and promising developments in recent years.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Purchased Database
  • 1.3.3. GVR's Internal Database
  • 1.3.4. Secondary Sources
  • 1.3.5. Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Information Analysis
  • 1.4.2. Market Formulation & Data Visualization
  • 1.4.3. Data Validation & Publishing
• 1.5. Model Details
  • 1.5.1. Commodity Flow Analysis (Model 1)
  • 1.5.2. Top Down Market Estimation (Model 2)
  • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
  • 1.5.4. Multivariate Analysis (Model 4)
• 1.6. List of Secondary Sources
• 1.7. List of Abbreviations
• 1.8. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Live Biotherapeutic Products And Microbiome CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High Potential of Live Biotherapeutic Products and Microbiome in Treating Chronic & Infectious Diseases
    • 3.2.1.2. Increase in Clinical Research on Live Biotherapeutic Products
    • 3.2.1.3. Increasing Demand for One-Stop-Shop CDMOs
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues in Outsourcing
    • 3.2.2.2. Availability of Substitutes
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Clinical Trial Volume Analysis, 2024
• 3.6. Industry Market Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Live Biotherapeutic Products and Microbiome CDMO Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Live Biotherapeutic Products and Microbiome CDMO Market Application Movement Analysis
• 4.3. Global Live Biotherapeutic Products and Microbiome CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. C. Difficle
  • 4.4.1. C. Difficle Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Crohn's disease
  • 4.5.1. Crohn's Disease Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. IBS
  • 4.6.1. IBS Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Diabetes
  • 4.7.1. Diabetes Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pharmaceutical Transportation Services Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2024 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size & Forecasts Trend Analysis, 2018 to 2030 (USD Million)
• 5.4. North America
  • 5.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Competitive scenario
    • 5.4.2.3. Regulatory scenario
    • 5.4.2.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Competitive scenario
    • 5.4.3.3. Regulatory scenario
    • 5.4.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Competitive scenario
    • 5.4.4.3. Regulatory scenario
    • 5.4.4.4. Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Competitive scenario
    • 5.5.2.3. Regulatory scenario
    • 5.5.2.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Competitive scenario
    • 5.5.3.3. Regulatory scenario
    • 5.5.3.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Competitive scenario
    • 5.5.4.3. Regulatory scenario
    • 5.5.4.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Competitive scenario
    • 5.5.5.3. Regulatory scenario
    • 5.5.5.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Competitive scenario
    • 5.5.6.3. Regulatory scenario
    • 5.5.6.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Denmark
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Competitive scenario
    • 5.5.7.3. Regulatory scenario
    • 5.5.7.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Norway
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Competitive scenario
    • 5.5.8.3. Regulatory scenario
    • 5.5.8.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Sweden
    • 5.5.9.1. Key country dynamics
    • 5.5.9.2. Competitive scenario
    • 5.5.9.3. Regulatory scenario
    • 5.5.9.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Competitive scenario
    • 5.6.2.3. Regulatory scenario
    • 5.6.2.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Competitive scenario
    • 5.6.3.3. Regulatory scenario
    • 5.6.3.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Competitive scenario
    • 5.6.4.3. Regulatory scenario
    • 5.6.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. Australia
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Competitive scenario
    • 5.6.5.3. Regulatory scenario
    • 5.6.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. South Korea
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Competitive scenario
    • 5.6.6.3. Regulatory scenario
    • 5.6.6.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key country dynamics
    • 5.6.7.2. Competitive scenario
    • 5.6.7.3. Regulatory scenario
    • 5.6.7.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Competitive scenario
    • 5.7.2.3. Regulatory scenario
    • 5.7.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Competitive scenario
    • 5.7.3.3. Regulatory scenario
    • 5.7.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Competitive scenario
    • 5.8.2.3. Regulatory scenario
    • 5.8.2.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key country dynamics
    • 5.8.3.2. Competitive scenario
    • 5.8.3.3. Regulatory scenario
    • 5.8.3.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key country dynamics
    • 5.8.4.2. Competitive scenario
    • 5.8.4.3. Regulatory scenario
    • 5.8.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key country dynamics
    • 5.8.5.2. Competitive scenario
    • 5.8.5.3. Regulatory scenario
    • 5.8.5.4. Israel market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Competition Categorization
• 6.2. Company Market Assessment Analysis, 2024
• 6.3. Company Profiles
  • 6.3.1. Arrant Bio
    • 6.3.1.1. Company overview
    • 6.3.1.2. Financial performance
    • 6.3.1.3. Service benchmarking
    • 6.3.1.4. Strategic initiatives
  • 6.3.2. 4D Pharma
    • 6.3.2.1. Company overview
    • 6.3.2.2. Financial performance
    • 6.3.2.3. Service benchmarking
    • 6.3.2.4. Strategic initiatives
  • 6.3.3. Cerbios
    • 6.3.3.1. Company overview
    • 6.3.3.2. Financial performance
    • 6.3.3.3. Service benchmarking
    • 6.3.3.4. Strategic initiatives
  • 6.3.4. Biose Industrie
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Service benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Assembly Biosciences, Inc.
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Service benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Wacker Chemie AG
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Service benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Quay Pharmaceuticals
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Service benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. NIZO
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Service benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Lonza
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Service benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Inpac Probiotics
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Service benchmarking
    • 6.3.10.4. Strategic initiatives